IRCCS Casa Sollievo della Sofferrenza opera di San Pio da Pietrelcina

Informazioni aggiuntive

• Pubblicazioni Scientifiche:

  Totale pubblicazioni a partire dal 2011: 128

  
  

  Anno

  2019; 8(4): SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study. Mangia A, Cenderello G, Copetti M, Verucchi G, Piazzolla V, Lorusso C, Santoro R, Squillante MM, Orlandini A, Minisini R, Ciancio A

  2019; 14(5): e0215783 SVR12 rates higher than 99% after sofosbuvir/velpatasvir combination in HCV infected patients with F0-F1 fibrosis stage: A real world experience. Mangia A, Piazzolla V, Giannelli A, Visaggi E, Minerva N, Palmieri V, Carraturo I, Potenza D, Napoli N, Lauletta G, Tagarielli V, Santoro R, Piccigallo E, De Gioia S, Chimenti A, Cuccorese G, Metrangolo A, Mazzola M, Agostinacchio E, Mennea G, Sabbà C, C

  2018; (): Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus. Vergara C, Thio CL, Johnson E, Kral AH, O'Brien TR, Goedert JJ, Mangia A, Piazzolla V, Mehta SH, Kirk GD, Kim AY, Lauer GM, Chung RT, Cox AL, Peters MG, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Busch MP, Alexander G, Rosen HR, Murphy EL, Latan

  2018; 97(27): e11307 Effectiveness and safety of simeprevir-based regimens for hepatitis C in Italy: The STIly observational study. Gaeta GB, Aghemo A, Menzaghi B, D'Offizi G, Giorgini A, Hasson H, Brancaccio G, Palma M, Termini R, STIly Study Group.

  2018; 154(6): 1764-1777.e7 TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. Boni C, Vecchi A, Rossi M, Laccabue D, Giuberti T, Alfieri A, Lampertico P, Grossi G, Facchetti F, Brunetto MR, Coco B, Cavallone D, Mangia A, Santoro R, Piazzolla V, Lau A, Gaggar A, Subramanian GM, Ferrari C

  2018; 25(8): 920-929 Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review. Goossens N, de Vito C, Mangia A, Clément S, Cenderello G, Barrera F, D'Ambrosio R, Coppola N, Zampino R, Stanzione M, Adinolfi LE, Wedemeyer H, Semmo N, Müllhaupt B, Semela D, Malinverni R, Moradpour D, Heim M, Trincucci G, Rubbia-Brandt L, Negro F, BOS

  2018; 48(5): 564-573 A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, Metwally M, Bayoumi A, Boonstra A, Brouwer WP, Smedile A, Abate ML, Loglio A, Douglas MW, Khan A, Santoro R, Fischer J, Leeming DJ, Liddle C, George J, Eslam M

  2018; (): Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience. Alberti A, Angarano G, Colombo M, Craxì A, Di Marco V, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P

  2018; 22(20): 7024-7033 Optimising management of patients with hepatitis C virus in the age of direct-acting antivirals: results of a Delphi consensus. Di Marco V, Alberti A, Angarano G, Colombo M, Di Perri G, Gaeta GB, Ippolito G, Mangia A, Pasqualetti P, Craxì A

  2018; 13(7): e0200568 Real life rates of sustained virological response (SVR) and predictors of relapse following DAA treatment in genotype 3 (GT3) patients with advanced fibrosis/cirrhosis. Mangia A, Losappio R, Cenderello G, Potenza D, Mazzola M, De Stefano G, Terreni N, Copetti M, Minerva N, Piazzola V, Bacca D, Palmieri V, Sogari F, Santoro R

  2017; 153(5): 1448-1449 TLL1 rs17047200 Increases the Risk of Fibrosis Progression in Caucasian Patients With Chronic Hepatitis C. John M, Metwally M, Mangia A, Romero-Gomez M, Berg T, Sheridan D, George J, Eslam M

  2017; 7(1): 15843 Fine-mapping of genetic loci driving spontaneous clearance of hepatitis C virus infection. Huang H, Duggal P, Thio CL, Latanich R, Goedert JJ, Mangia A, Cox AL, Kirk GD, Mehta S, Aneja J, Alric L, Donfield SM, Cramp ME, Khakoo SI, Tobler LH, Busch M, Alexander GJ, Rosen HR, Edlin BR, Segal FP, Lauer GM, Thomas DL, Daly MJ, Chung RT, Kim AY

  2017; (): Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimens. Bhardwaj N, Ragonnet-Cronin M, Murrell B, Chodavarapu K, Martin R, Chang S, Miller MD, Feld JJ, Sulkowski M, Mangia A, Wertheim JO, Osinusi A, McNally J, Brainard D, Mo H, Svarovskaia ES

  2017; 16(5): 523-541 International therapeutic guidelines for patients with HCV-related extrahepatic disorders. A multidisciplinary expert statement. Zignego AL, Ramos-Casals M, Ferri C, Saadoun D, Arcaini L, Roccatello D, Antonelli A, Desbois AC, Comarmond C, Gragnani L, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P, ISG-EHCV.

  2017; 49(5): 795-800 IFN-λ3, not IFN-λ4, likely mediates IFNL3-IFNL4 haplotype-dependent hepatic inflammation and fibrosis. Eslam M, McLeod D, Kelaeng KS, Mangia A, Berg T, Thabet K, Irving WL, Dore GJ, Sheridan D, Grønbæk H, Abate ML, Hartmann R, Bugianesi E, Spengler U, Rojas A, Booth DR, Weltman M, Mollison L, Cheng W, Riordan S, Mahajan H, Fischer J, Nattermann J, Dougla

  2017; 66(6): 1282-1299 Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. Ramos-Casals M, Zignego AL, Ferri C, Brito-Zerón P, Retamozo S, Casato M, Lamprecht P, Mangia A, Saadoun D, Tzioufas AG, Younossi ZM, Cacoub P, International Study Group of Extrahepatic Manifestations related to HCV (ISG-EHCV).

  2017; 37(4): 514-528 Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M,

  2017; 66(5): 910-918 NS5A resistance-associated substitutions in patients with genotype 1 hepatitis C virus: Prevalence and effect on treatment outcome. Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, Svarovskaia E, Dvory-Sobol H, Doehle B, Hedskog C, Yun C, Brainard DM, Knox S, McHutchison JG, Miller MD, Mo H, Chuang WL, Jacobson I, Dore GJ, Sulkowski M

  2017; 65(6): 1840-1850 The membrane-bound O-acyltransferase domain-containing 7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. Thabet K, Chan HLY, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML, Wong VW, Nazmy M, Fischer J, Liddle C, George J, Eslam M

  Annals of gastroenterology 2017; 30(3): 327-343 Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study. Mangia A, Foster GR, Berg CP, Curescu M, Ledinghen V, Habersetzer F, Manolakopoulos S, Negri E, Papatheodoridis G, Ahlers S, Castillo M, Bakalos G, Mauss S, PegBase Group Investigators.

  2017; 67(4): 680-686 Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. Susser S, Dietz J, Schlevogt B, Zuckerman E, Barak M, Piazzolla V, Howe A, Hinrichsen H, Passmann S, Daniel R, Cornberg M, Mangia A, Zeuzem S, Sarrazin C

  2017; (): Long-term persistence of HCV NS5A resistance associated substitutions after treatment with the HCV NS5A inhibitor, ledipasvir, without sofosbuvir. Wyles D, Mangia A, Cheng W, Shafran S, Schwabe C, Ouyang W, Hedskog C, McNally J, Brainard DM, Doehle BP, Svarovskaia E, Miller MD, Mo H, Dvory-Sobol H

  2017; (): Sofosbuvir/Velpatasvir in Patients With Hepatitis C Virus Genotypes 1-6 and Compensated Cirrhosis or Advanced Fibrosis. Asselah T, Bourgeois S, Pianko S, Zeuzem S, Sulkowski M, Foster GR, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Gane EJ, Feld JJ, Mangia A

  2017; (): The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes. Carrai P, Morelli C, Cordone G, Romano A, Tamé M, Lionetti R, Pietrosi G, Lenci I, Piai G, Russo FP, Coppola C, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Martini S, Toniutto P, ITACOPS study group.

  2017; 46(6): 629-630 Editorial: good news to patients with thalassaemia-HCV clearance made easy with direct acting antivirals. Authors' reply. Mangia A, Piazzolla V, Santoro R

  2017; 46(4): 424-431 Randomised clinical trial: sofosbuvir and ledipasvir in patients with transfusion-dependent thalassaemia and HCV genotype 1 or 4 infection. Mangia A, Sarli R, Gamberini R, Piga A, Cenderello G, Piazzolla V, Santoro R, Caruso V, Quarta A, Ganga R, Copetti M, Forni G

  2016; (): Sofosbuvir and Ribavirin for genotype 2 HCV infected patients with cirrhosis: a real life experience. Mangia A, Susser S, Piazzolla V, Agostinacchio E, De Stefano G, Palmieri V, Spinzi G, Carraturo I, Potenza D, Losappio R, Arleo A, Miscio M, Santoro R, Sarrazin C, Copetti M

  Minerva gastroenterologica e dietologica. 2016; 62(2): 167-82 The current treatment of Hepatitis C. Arleo A, Mangia A

  2016; 5(1): 1990 IL28B genotype is associated with cirrhosis or transition to cirrhosis in treatment-naive patients with chronic HCV genotype 1 infection: the international observational Gen-C study. Mangia A, De Ledinghen V, Bailly F, Brahm J, Keiss J, Valantinas J, Rasmann N, Messinger D, Tatsch F, Bakalos G, Foster GR, Gen-C study group.

  2016; 12(4): 770-80 Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection. Ripoli M, Angelico R, Sacco P, Ceglie A, Mangia A

  2016; 63(11): 1479-1481 Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials. Grebely J, Dore GJ, Zeuzem S, Aspinall RJ, Fox R, Han L, McNally J, Osinusi A, Brainard DM, Subramanian GM, Natha M, Foster GR, Mangia A, Sulkowski M, Feld JJ

  2016; 7(): 12757 MBOAT7 rs641738 increases risk of liver inflammation and transition to fibrosis in chronic hepatitis C. Thabet K, Asimakopoulos A, Shojaei M, Romero-Gomez M, Mangia A, Irving WL, Berg T, Dore GJ, Grønbæk H, Sheridan D, Abate ML, Bugianesi E, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Spengler U, Nattermann J, Wahid A, Rojas A, White R, Douglas

  2016; 15(12): 1145-1160 International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M, Lamprecht P, Mangia A, Tzioufas AG, Younossi ZM, Cacoub P, ISG-EHCV coauthors.

  2016; (): Sofosbuvir and Velpatasvir Combination Improves Outcomes Reported by Patients With HCV Infection, Without or with Compensated or Decompensated Cirrhosis. Younossi ZM, Stepanova M, Feld J, Zeuzem S, Sulkowski M, Foster GR, Mangia A, Charlton M, O'Leary JG, Curry MP, Nader F, Henry L, Hunt S

  2016; 71(3): 739-50 HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels. Di Maio VC, Cento V, Di Paolo D, Aragri M, De Leonardis F, Tontodonati M, Micheli V, Bellocchi MC, Antonucci FP, Bertoli A, Lenci I, Milana M, Gianserra L, Melis M, Di Biagio A, Sarrecchia C, Sarmati L, Landonio S, Francioso S, Lambiase L, Nicolini LA, Ma

  2016; 63(4): 1112-9 Safety and efficacy of ledipasvir/sofosbuvir for the treatment of genotype 1 hepatitis C in subjects aged 65 years or older. Saab S, Park SH, Mizokami M, Omata M, Mangia A, Eggleton E, Zhu Y, Knox SJ, Pang P, Subramanian M, Kowdley K, Afdhal NH

  2016; 36(7): 971-6 The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Mangia A, Arleo A, Copetti M, Miscio M, Piazzolla V, Santoro R, Squillante MM

  2016; 64(1): 34-46 Diverse impacts of the rs58542926 E167K variant in TM6SF2 on viral and metabolic liver disease phenotypes. Eslam M, Mangia A, Berg T, Chan HL, Irving WL, Dore GJ, Abate ML, Bugianesi E, Adams LA, Najim MA, Miele L, Weltman M, Mollison L, Cheng W, Riordan S, Fischer J, Romero-Gomez M, Spengler U, Nattermann J, Rahme A, Sheridan D, Booth DR, McLeod D, Powell E,

  2016; 11(3): e0151703 Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort. Foster GR, Coppola C, Derbala M, Ferenci P, Orlandini A, Reddy KR, Tallarico L, Shiffman ML, Ahlers S, Bakalos G, Hassanein T, GUARD-C Study Group

  2016; 374(17): 1687-8 Sofosbuvir and Velpatasvir for Patients with HCV Infection. Foster GR, Mangia A, Sulkowski M

  2016; (): Polymorphisms in STAT4 are not associated with treatment response and spontaneous clearance of hepatitis C virus in europeans. Asimakopoulos A, Mangia A, Dore GJ, Lloyd AR, George J, Eslam M

  2016; 48(8): 860-8 AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). Women in Hepatology Group, Italian Association for the Study of the Liver (AISF)

  2016; (): Ribavirin-Free Regimen With Sofosbuvir and Velpatasvir Is Associated With High Efficacy and Improvement of Patient-Reported Outcomes in Patients With Genotypes 2 and 3 Chronic Hepatitis C: Results From Astral-2 and -3 Clinical Trials. Younossi ZM, Stepanova M, Sulkowski M, Foster GR, Reau N, Mangia A, Patel K, Bräu N, Roberts SK, Afdhal N, Nader F, Henry L, Hunt S

  2015; 10(2): e0117420 Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. De Re V, Caggiari L, De Zorzi M, Repetto O, Zignego AL, Izzo F, Tornesello ML, Buonaguro FM, Mangia A, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Vaccher E, Berretta M, Mazzaro C, Libra M, Gini A, Zucchetto A, Cannizzaro R, De Paoli P

  2015; 6(): 6422 Interferon-? rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease. Eslam M, Hashem AM, Leung R, Romero-Gomez M, Berg T, Dore GJ, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Mangia A, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Powell E, Nattermann J, Riordan S, McLeod D, Armstron

  2015; 62(1): 79-86 Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: An integrated safety and efficacy analysis. Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N

  2015; 2015(): 731469 The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. Bertino G, Demma S, Ardiri A, Proiti M, Mangia A, Gruttadauria S, Toro A, Di Carlo I, Malaguarnera G, Bertino N, Malaguarnera M, Malaguarnera M

  2015; 62(1): 25-30 Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials. Alqahtani SA, Afdhal N, Zeuzem S, Gordon SC, Mangia A, Kwo P, Fried M, Yang JC, Ding X, Pang PS, McHutchison JG, Pound D, Reddy KR, Marcellin P, Kowdley KV, Sulkowski M

  2015; 10(7): e0134594 The Cytokinome Profile in Patients with Hepatocellular Carcinoma and Type 2 Diabetes. Capone F, Guerriero E, Colonna G, Maio P, Mangia A, Marfella R, Paolisso G, Izzo F, Potenza N, Tomeo L, Castello G, Costantini S

  2015; 10(9): e0138503 Final Results of the Telaprevir Access Program: FibroScan Values Predict Safety and Efficacy in Hepatitis C Patients with Advanced Fibrosis or Cirrhosis. Lepida A, Colombo M, Fernandez I, Abdurakhmanov D, Abrao Ferreira P, Strasser SI, Urbanek P, Mangia A, Calleja JL, Iraqi W, DeMasi R, Lonjon-Domanec I, Moreno C, Wedemeyer H

  2015; (): Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. Foster GR, Afdhal N, Roberts SK, Bräu N, Gane EJ, Pianko S, Lawitz E, Thompson A, Shiffman ML, Cooper C, Towner WJ, Conway B, Ruane P, Bourlière M, Asselah T, Berg T, Zeuzem S, Rosenberg W, Agarwal K, Stedman CA, Mo H, Dvory-Sobol H, Han L, Wang J, McNall

  2015; (): Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuz

  2015; (): FibroGENE: A gene-based model for staging liver fibrosis. Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HL, Irving WL, Sheridan D, Abate ML, Adams LA, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Nattermann J, Riordan S, Miele L, Kelaeng KS, Ampuero J, Ahlen

  2014; 46S5(): S179-S185 Overall efficacy and safety results of sofosbuvir-based therapies in Phase II and III studies. Mangia A, Piazzolla V

  2014; 9(10): e110284 Individualized treatment of genotype 1 naïve patients: an italian multicenter field practice experience. Mangia A, Cenderello G, Orlandini A, Piazzolla V, Picciotto A, Zuin M, Ciancio A, Brancaccio G, Forte P, Carretta V, Zignego AL, Minerva N, Brindicci G, Marignani M, Baroni GS, Bertino G, Cuccorese G, Mottola L, Ripoli M, Pirisi M

  2014; (): Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, Marenco S, Piovesan S, Chemello L, Babudieri S, Moretti A, Gea F, Colletta C, Perez-Alvarez R, Forns X, Larrubia JR, Arenas J, Crespo J, Calvaruso V, Ceccherini Silbers

  2014; 34(7): e308-16 Prognostic factors of hepatic decompensation and hepatocellular carcinoma in patients with transfusion-acquired HCV infection. Zavaglia C, Silini E, Mangia A, Airoldi A, Piazzolla V, Vangeli M, Stigliano R, Foschi A, Mazzarelli C, Tinelli C

  2014; (): Genome-wide association study of hepatitis C virus- and cryoglobulin-related vasculitis. Zignego AL, Wojcik GL, Cacoub P, Visentini M, Casato M, Mangia A, Latanich R, Charles ED, Gragnani L, Terrier B, Piazzola V, Dustin LB, Khakoo SI, Busch MP, Lauer GM, Kim AY, Alric L, Thomas DL, Duggal P

  2014; (): Interleukin-28B genetic variants in untreated Italian HCV-infected patients: a multicentre study. Mottola L, Cenderello G, Piazzolla VA, Forte P, Carretta V, Mecenate F, Brancaccio G, Minisini R, Zuin M, Terreni N, Monti M, Colombo AE, Nosotti L, Minerva N, Luzzitelli I, Kostandini A, Cuccorese G, Russello M, Santoro R, Mangia A

  2014; 9(9): e106424 Clinical Significance of the CCR5delta32 Allele in Hepatitis C. Morard I, Clément S, Calmy A, Mangia A, Cerny A, De Gottardi A, Gorgievski M, Heim M, Malinverni R, Moradpour D, Müllhaupt B, Semela D, Pascarella S, Bochud PY, Negro F, Swiss Hepatitis C Cohort Study Group

  2014; 20(28): 9261-9 Cytokinome profile evaluation in patients with hepatitis C virus infection. Capone F, Guerriero E, Colonna G, Maio P, Mangia A, Castello G, Costantini S

  2014; 471(1-2): 173-181 Phyto-liposomes as nanoshuttles for water-insoluble silybin-phospholipid complex. Angelico R, Ceglie A, Sacco P, Colafemmina G, Ripoli M, Mangia A

  2014; (): Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3. Zeuzem S, Dusheiko GM, Salupere R, Mangia A, Flisiak R, Hyland RH, Illeperuma A, Svarovskaia E, Brainard DM, Symonds WT, Subramanian GM, McHutchison JG, Weiland O, Reesink HW, Ferenci P, Hézode C, Esteban R, the VALENCE Investigators

  2014; 60: S495 Modeling predicts clinically meaningful SVR rates in genotype 1 treatment-experienced patients based on results in genotype 1 treatment-naive patients treated with sofosbuvir + peginterferon + ribavirin for 12 weeks Muir A., Nelson D.R., Gordon S.C., Feld J.J., Patel K., Lawitz E., Sheikh A.M., Brainard D.M., Symonds W.T., McHutchison J.G., Bekele B.N., Mangia A., Gane E.J.

  2014; (): Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P,

  2014; 60: s473 rs12979860 IL28B GENOTYPE IS ASSOCIATED WITH ADVANCED FIBROSIS IN HCV GENOTYPE 1-INFECTED EUROPEAN PATIENTS WITH CHRONIC HEPATITIS C: RESULTS FROM THE INTERNATIONAL GEN-C STUDY Mangia A., De Ledinghen V., Bailly F., Brahm J., Keiss J., Valantinas J., Rasmann N., Riachi G., Messinger D., Caputo A., Foster G.R., on behalf of the Gen-C Study Group.

  2014; 60: S523-S524 All oral fixed-dose combination sofosbuvir/ledipasvir with or without ribavirin for 12 or 24 weeks in treatment-naive genotype 1 HCV-infected patients: the phase 3 ion-1 study Mangia A., Marcellin P., Kwo P., Foster G.R., Buti M., Brau N., Muir A., Yang J.C., Mo H., Ding X., Pang P.S., Symonds W.T., McHutchison J.G., Zeuzem S., Afdhal N.

  2014; 60: s455 Impact of safety-related dose reductions and discontinuations (SR-RD) on sustained virological response (SVR) in treatment-naive chronic hepatitis C patients receiving peginterferon alfa-2a/ribavirin: results from guard-c Foster G.R., Coppola C., Curescu M., Derbala M., Esmat G., Ferenci P., Flisiak R., Lengyel G., Mangia A., Orlandini A., Reddy K.R., M. Rodriguez-Torres, Shiffman M.L., Sporea I., Tallarico L., Ahlers S., Bakalos G., Wat C., Hassanein T.

  2014; (): IFNL3 polymorphisms predict response to therapy in chronic hepatitis C genotype 2/3 infection. Eslam M, Leung R, Romero-Gomez M, Mangia A, Irving WL, Sheridan D, Spengler U, Mollison L, Cheng W, Bugianesi E, McLeod D, Zaitoun AM, Attino V, Goeltz D, Nattermann J, Douglas M, Booth DR, George J, Ahlenstiel G

  BIOMED research international 2014; 2014(): 710642 Impact of Immunogenetic IL28B Polymorphism on Natural Outcome of HCV Infection. De Re V, Gragnani L, Fognani E, Piluso A, Izzo F, Mangia A, Crovatto M, Gava G, Casarin P, Sansonno D, Racanelli V, De Vita S, Pioltelli P, Caggiari L, De Zorzi M, Berretta M, Gini A, Zucchetto A, Buonaguro FM, De Paoli P, Zignego AL

  2014; 60: S449 Long term follow-up of patients treated with sofosbuvir in the fission, positron, fusion and neutrino phase 3 studies W. Cheng, S. Shafran, K. Beavers, H. Mo, J. McNally, D.M. Brainard, W.T. Symonds, M. Chojkier, Mangia A., C. Schwabe

  2014; 60: S470 Efficacy And Safety Of Boceprevir-Based Therapy In HCVG1 Treatment-Experienced Patients With Advanced Fibrosis/Cirrhosis: The Italian And Spanish NPP Early Access Program S. Bruno, S. Bollani, J.M. Pascasio, A.L. Zignego, V. Di Marco, C Magni, M. Rizzetto, A. Ciancio, A. Alberti, S. Piovesan, Mangia A., J. De la Revilla, J.R. Larrubia, F. Gea, S. Babudieri, R. Perez-Alvarez, C. Colletta, R. Barcena, X. Forns, M. Romero-Gom

  2013; 58(4): 1282A-1283A Genome wide association study of hepatitis C virus- and cryoglobulin-related vasculitis Zignego A.L., Wojcik G.L., Cacoub P., Visentini M., Fiorilli M., Terrier B., Mangia A., Latanich R., Charles E., Khakoo S.I., Busch M.P., Dustin L.B., Thomas D.L. , Duggo P.

  2013; 58(4): 733A Sofosbuvir + Ribavirin for 12 or 24 Weeks far Patients with HCV Genotype 2 or 3: thè VALENCE trial Zeuzem S., Dusheiko G.M., Sciupare R., Mangia A., Flisiak R., Hyland R.H., Illeperuma A., Svarovskaia E.S., Brainard D.M., Symonds W.T., McHutchison J.C., Weiland O., Reesink H.W., Ferenci P., Hezode C., Esteban R.

  2013; : 750A On Treatment HCV RNA as a Predictor of Virologie Response in Sofosbuvir-Containing Regimens for Genotype 2/3 HCV Infection: Analysis of the FISSION, POSITRON, and FUSION Studies Wyles D.L., Nelson D.R. , Swain M.G., Gish R.G., Ma J., McNally J., Bramare D.M., Symonds W.T., McHutchison J.G., Bernstein D.E., Thompson A.J., Mangia A., Jacobson I.M.

  2013; 58: S476 Effects of a new liposome-encapsulated formulation of silybin on hepatitis c virus infection Ripoli M., Angelico R., Piazzolla V., Santoro R., Mottola L., Petruzzellis D., Mangia A.

  2013; 58: S354 Correlation of il28b polymorphism with degree of fibrosis: analysis of treatment-naive and treatment-experienced caucasian patients infected with HCV genotype 1 in the gen-c study Mangia A., de Lédinghen V., Keiss J., Valantinas J., Brahm J., Rasmann N., Messinger D., Tatsch F., on behalf of the gen-C Study Group

  2013; 58(4): 752A Virologie Response Rates to Sofosbuvir-Containing Regimens Are Similar in Patients With and Without Traditional Negative Predictive Factors: A Retrospective Analysis of Phase 3 Data Mangia A., Kugelmas M., Eversori G.T., Minestrasi F., Ma J., McNally J., Brainard D.M., Symonds W.T., McHutchison J.G., Gane E.J., Shafran S.D., Chung R.T., Lawitz E.

  2013; 58: S3 Phase 3 randomized controlled trial of all-oral treatment with sofosbuvir + ribavirin for 12 weeks compared to 24 weeks of peg + ribavirin in treatment-naive gt2/3 hcv-infected patients (fission) Gane E., Lawitz E., Rodriguez-Torres M., Gordon S., Dvory-Sobol H., Arterburn S., McNally J., Brainard D.M., Symonds W.T., McHutchison J.G., Sheikh A., Mangia A.

  2013; 58: S334 Factors associated with intolerance to peginterferon alfa/ribavirin in treatment-na¨ive, cirrhotic/non-cirrhotic hcv genotype 1-infected patients: analysis of data from the multinational prophesys cohorts Firpi R., Reau N., Korner E., Hoop R., Han J., Mangia A., Ferenci P., Everson G.

  2013; : 754A A Bayesian Bridging Mode! Using Phase 3 Data in Treatment-Experienced HCV Genotype 3 Patients Demonstrates Extending Sofosbuvir+Ribavirin Treatment from 12 to 16 Weeks in Treatment-Naì've Genotype 3 Patients May Significanti/ Increase SVR Rates Nebiyou Bekeìe B., Nelson D.R., Gordon S.C., Felci J.J., Potei K., Lawiiz E., Sheikh A.M., Brainard D.M., Symonds W.T., McHutchison J.G., Mangia A., Gane E.J.

  JOURNAL OF HEPATOLOGY 2013; 58: S322 Hepatitis c treatment outcomes and predictors of response in treatment-naive patients treated with peginterferon alfa/ribavirin in real-world italian clinics compared with other countries: prophesys sub-analysis Ascione A., Bruno S., Coppola C., Mangia A., Orlandini A., Schmitz M., Deodato B., Puoti M., on behalf of the PROPHESYS 2

  2013; (): Triple therapy with first-generation Protease Inhibitors for patients with genotype 1 chronic hepatitis C: Recommendations of the Italian Association for the Study of the Liver (AISF). Italian Association for the Study of the Liver (AISF), Coco B, Caraceni P, Aghemo A, Bitetto D, Bruno R, Ciancio A, Marzioni M, Petta S, Rendina M, Valenti L, Review Board:

  2013; 57(3): 974-84 Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial. Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM, SPRINT-2 Trial Investigators

  2013; (): In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions. Mangia A, Bányai T, De Bartolomeo G, Gervain J, Habersetzer F, Mulkay JP, Ouzan D, Parruti G, Passariello N, Remy AJ, Rizzetto M, Shiffman ML, Tice AD, Schmitz M, Tatsch F, Rodriguez-Torres M

  2013; 59(2): 221-8 Treatment optimization and prediction of HCV clearance in patients with acute HCV infection. Mangia A, Santoro R, Copetti M, Massari M, Piazzolla V, Spada E, Cappucci G, Missale G, Mottola L, Agostinacchio E, Mauro Ld, Zuccaro O, Maio P, Pellegrini F, Folgori A, Ferrari C

  2013; : Insulin resistance, steatosis and hepatitis C virus Mangia A., Ripoli M.

  2013; 368(20): 1878-87 Sofosbuvir for previously untreated chronic hepatitis C infection. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, Schultz M, Davis MN, Kayali Z, Reddy KR, Jacobson IM, Kowdley KV, Nyberg L, Subramanian GM, Hyland RH, Arterburn S, Jiang D, McNally J, Brainard D, Symonds WT, McHutchison JG, Sheikh

  2013; 158(4): 235-45 Genome-wide association study of spontaneous resolution of hepatitis C virus infection: data from multiple cohorts. Duggal P, Thio CL, Wojcik GL, Goedert JJ, Mangia A, Latanich R, Kim AY, Lauer GM, Chung RT, Peters MG, Kirk GD, Mehta SH, Cox AL, Khakoo SI, Alric L, Cramp ME, Donfield SM, Edlin BR, Tobler LH, Busch MP, Alexander G, Rosen HR, Gao X, Abdel-Hamid M, Apps R

  BioMed Research International 2013; : Impact of immunogenetic IL28B polymorphism on natural outcome of HCV infection De Re V., Gragnani L., Fognani E., Piluso A., Izzo F., Tornesello M.L., Mangia A., Crovatto M., Graziella G., Casarin P., Sansonno D., Racanelli V., De Vita S., Pioltelli P., Caggiari L., De Zorzi M., Massimiliano B., Gini A., Zucchetto A., Buonaguro F.M.

  2013; 58(6): 1259 Usefulness of Lead-In phase in determining risk/benefit of telaprevir treatment in patients with HCV cirrhosis. Bruno S, Mangia A

  2013; 58(1): 65-72 Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Arena U, Lupsor Platon M, Stasi C, Moscarella S, Assarat A, Bedogni G, Piazzolla V, Badea R, Laffi G, Marra F, Mangia A, Pinzani M

  2013; (): Reply to: "Built-in bias in HCV clearance in acute hcv infection" Copetti M, Pellegrini F, Piazzolla V, Mangia A

  VIII Workshop "Hot topics in Hepatology" 2012; 20/21 gennaio 2012: Modena Significato e ruolo del polimorfismo di IL288 nella gestione del paziente con epatite cronica da HCV Mangia A

  VIII Convegno Nazionale aggiornamenti in Epatologia e Gastroenterologia 2012; 15/16 ottobre 2012: Verona Gestione terapeutica del paziente con epatite cronica C: dai trials alla pratica clinica Mangia A

  HCV2012 - 19th International Symposium on hepatitis C virus and related viruses 2012; Venezia 5-9 ottobre 2012: p 301 Effects of silybin on Hepatitis C virus replications: an "in vitro" study Ripoli M, Piazzolla V, Mottola L, Santoro R, Petruzzellis D, Mangia A,

  2012; 56, nr 4: 588a p811 Baseline predictors of null-response to geginterferon (PegIFN) ?2a (40KD)/ribavirin (RBV) in treatment naive patients with chronic hepatitis C (CHC) infected with HCV genotype 1: analysis of data from the multinational PROPHESYS cohorts Mangia A

  2012; 56 -nr 4: 1001a -p1737 Benefit of weight based dosages of Ribavirin (RBV) in combination with PegInterferon (PegIFN) ?2a in naive patients with HCV2 and HCV3: results of an Italian Randomized Controlled Trial, the WRITE study Mangia A

  HCV2012 - 19th International Symposium on hepatitis C virus and related viruses 2012; Venezia - 5-9 ottobre 2012: p.317 Different KIR/HLA gene combibations associated to the development of HCV-related diseases Mangia A

  2012; Ottobre 2012 - 1791: 1028a Optimizing ribavirin dose is critical for sustained viral response in patients with thalassemia major tretated for chronic hepatitis C Santoro R, Piazzolla V, Mottola L, Dello Iacono N, Mangia A

  2012; 143(3): 608-18.e1-5 Factors that predict response of patients with hepatitis C virus infection to boceprevir. Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR, SPRINT-2 and RESPOND-2 Investigators

  2012; 56(6): 2039-50 High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials. Marcellin P, Cheinquer H, Curescu M, Dusheiko GM, Ferenci P, Horban A, Jensen D, Lengyel G, Mangia A, Ouzan D, Puoti M, Rodriguez-Torres M, Shiffman ML, Schmitz M, Tatsch F, Rizzetto M

  Therapy in Liver Diseases 2012; (): 33-38 How can we im prove svr rates in patients with genotype 2/3 hcv infection? Mangia A, Mottola L

  2012; (): Update on the treatment of patients with non-genotype 1 HCV infection. Mangia A, Mottola L, Piazzolla V

  2012; (): Futility of antiviral treatments for hepatitis C: An evolving concept entering the direct antiviral agents era. Bruno S, Mangia A

  2012; 56 - 1135: s448 IL28B CC. Genotype is associated with higher on-treatment-response rates in PTS with HCV-3: interim results of the write study Piazzolla V, Forte P, Francavilla R, Barbarini G, Mecenate F, Carrado M, Minerva G, Bacca D, Carretta V, Pellicelli A, Romano M, Montalto G, Zignego L, Nosotti L, De Luna A, Agostinacchio E, Cuccorese G, Luchi S, Bertino G, Santoro R, Mottola L, Petruzzel

  2012; 56 - 1134: s447 Premature treatment discontinuation of PEG-INFa - 2A/RBV due to good viral responses and insufficient viral responses among HCV genotype 1, 2 and 3 patients from prophesys Mangia A, Banyai T, De Bartolomeo G, Habersetzer F, Mulkay JP, Ouzan D, Parruti G, Passariello N, Gervain J, Remy AJ, Rizzetto M, Shiffman ML, Tice AD, Schmitz M, Tatsch F, Rodriguez-Torres M,

  2012; 56 -1088: s427-s428 Rates and predictors of sustained virological response and relapse in italian naive mono-infected chronic hepatitis c patients treated with peginterferon alfa/ribavirin: prophesys 2 final analysis Ascione A, Carosi G, Mangia A, Puoti M, Ordlandini A, Coppola C, Schmitz M, Golotta C, Rizzetto M

  2012; 56: s426 PEG-interferon and ribavirin in HCV-related cirrhotic patients with profound thrombocytopenia Andriulli A, Iacobellis A, Iannacone C, Angarano G, Adinolfi A, Persico M, Mangia A, Fattovich G, Capra F, Rizzetto M, Golotta C

  Current Gastroenterology Reports 2012; 14(1): 87-93 Treatment of non-genotype 1 hepatitis C virus patients. Mangia A, Mottola L

  2012; 19 Suppl 1(): 52-9 Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? Ciancio A, Andreone P, Kaiser S, Mangia A, Milella M, Solà R, Pol S, Tsianos E, De Rosa A, Camerini R, McBeath R, Rizzetto M

  2012; 32 Suppl 1(): 135-40 What's new in HCV genotype 2 treatment. Mangia A, Mottola L

  2011; 16(8): 1309-16 IL28B CC-genotype association with HLA-DQB1*0301 allele increases the prediction of spontaneous HCV RNA clearance in thalassaemic HCV-infected patients. Mangia A, Santoro R, Sarli R, Mottola L, Piazzolla V, Petruzzellis D, Bacca D, Clemente R, Copetti M, di Mauro L, Lotti G, Sacco M, Stefano I

  2011; AASLD 2011: 824A Worldwide experience treating Chronic Hepatitis C (CHC) with Peginterferon Alfa (PEGIFN/a)/Ribavirin (RBV): final results from 7163 naive, mono-infected patients (PTS) enrolled in the large multinational prophesys cohort study Marcellin P, Cheinquer H, Mangia A et al

  2011; 54: S525 Lack of association between IL28B variants and HBSAG clearance after interferon treatment Mangia A, Santoro R, Mottola L, Fasano M, Minerva N, Bacca D, Piazzolla V, Carretta V, Termite A, Agostinacchio E, Facciorusso D, Petruzzellis D, Santantonio T

  2011; 31(1): 36-41 Individualizing treatment duration in hepatitis C virus genotype 2/3-infected patients. Mangia A

  2011; 34(10): 1202-16 The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Sebastiani G, Castera L, Halfon P, Pol S, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A

  2011; 35(1): 92-104 Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Sebastiani G, Halfon P, Castera L, Mangia A, Di Marco V, Pirisi M, Voiculescu M, Bourliere M, Alberti A

  2011; 43 Suppl 4(): S331-43 Chronic viral hepatitis: the histology report. Guido M, Mangia A, Faa G, Gruppo Italiano Patologi Apparato Digerente (GIPAD), Società Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP)

  2011; 54(4): 403A-404A Treatment Of Patients With Acute Hcv Monoinfection May Be Delayed After Week 24 According With Il28b Single Nucleotide Polymorphisms (Snp) Results And Independently Of Hepatitis C Virus (Hcv) Genotype Mangia A. et al.

  2011; 129(3): 536-45 High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome. Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, Balsamo T, Storlazzi CT, Ripoli M, Rinaldi M, Valori VM, Latiano TP, Maiello E, Stanziale P, Carella M, Mangia A, Pellegrini F, Bisceglia M, Muda AO, Altomare V, Murgo R, Fazio VM, Parrella P

  2011; (): Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Copetti M, Minerva N, Petruzzellis D, Mottola L, Bacca D, McHutchison JG

  2011; 364(13): 1195-206 Boceprevir for untreated chronic HCV genotype 1 infection. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators

  2011; 53(2): 389-95 Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, Patel K, Muir AJ, Shianna KV, Mottola L, Petruzzellis D, Romano M, Sogari F, Facciorusso D, Goldstein DB, McHutchison JG, Mangia A

  2011; (): Response-guided peg-interferon plus ribavirin treatment duration in chronic hepatitis C: Meta-analyses of randomized, controlled trials and implications for the future. Di Martino V, Richou C, Cervoni JP, Sanchez-Tapias JM, Jensen DM, Mangia A, Buti M, Sheppard F, Ferenci P, Thévenot T

  2011; 54(s1): 339-340 Genetic predictors of steatosis and fibrosis in non alcoholic fatty liver disease (NAFLD) Mangia A, Mottola L, Petruzzellis D, Piazzolla V, Garrubba M, Di Paola R, Santoro R, Trischitta V, Villella M, Fanelli R, Vanni E, Seripa D, Pilotto A, Bugianesi E, Guido M, Santini SA

  2011; 53(1): 336-45 Hepatitis C pharmacogenetics: state of the art in 2010. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, Shianna KV, Tanaka Y, Thomas DL, Booth DR, Goldstein DB, Pharmacogenetics and Hepatitis C Meeting Participants

  2011; 43(3): 177-9 IL28B: A new wager in the skyline of hepatitis C virus infection. Mangia A

  {accordionfaq faqid=accordion3 faqclass="lightnessfaq defaulticon headerbackground headerborder contentbackground contentborder round5" active=0}